Impact of COVID-19 on clinical trials continuing, say researchers
An analysis of the impact of COVID-19 on clinical trials has shown this is increasing, with many sites unable to fully resume practice.
List view / Grid view
An analysis of the impact of COVID-19 on clinical trials has shown this is increasing, with many sites unable to fully resume practice.
Reeti Banerjee explains why the use of sterile packaging for medicines will see a growth in the near future, mostly due to the COVID-19 pandemic.
The Russian Direct Investment Fund (RDIF) said the supply of the COVID-19 vaccine should enable 25 percent of the population to be vaccinated.
The companies and European Commission will soon enter contract negotiations for the supply of their investigational COVID-19 vaccine candidate BNT162b2.
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
Nine biopharma CEOs pledged to make the integrity of the scientific process and sufficient supply priorities in the development of COVID-19 vaccines.
Preliminary data from Phase I/II trails evaluating the vaccine reveal 100 percent of participants had a humoral and cellular response, with no serious adverse events reported.
The trial will evaluate the safety, tolerability and immunogenicity of the duo’s COVID-19 recombinant protein-based vaccine candidate in 440 healthy US participants.
A trial has shown that COVID-19 patients treated with the steroid hydrocortisone had a 93 percent chance of a better outcome from the coronavirus.
Liz Thorn outlines the benefits that in vitro diagnostics can bring to the world in light of the current COVID-19 pandemic.
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
The Investigational New Drug Application (IND) is for a Phase II trial evaluating the safety and efficacy of FSD201 (ultramicronized PEA) in hospitalised COVID-19 patients.
Scientists have shown that treating COVID-19 patients with severe respiratory complications with an IL-6 signalling inhibitor improved their symptoms.
The clinical study will evaluate the efficacy of AZD1222, a COVID-19 vaccine candidate, in preventing symptomatic COVID-19 at 80 sites across the US.
The FDA has expanded the Emergency Use Authorisation for Veklury (remdesivir) to treat all hospitalised patients with COVID-19.